Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
Rachel breaks down why autoimmune thyroid diseases (AITD) are systemic, immune-mediated and impact far more than the thyroid gland alone - affecting everything from ovarian to cardiac tissues
IGF-1 Lr3 (Insulin-like Growth Factor-I Long R3) is an 83 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Arg for the Glu at position 3 (hence R3), as well as a 13 amino acid extension peptide at the N-terminus
American Journal of Cardiology, Volume 222, 121 - 130
